NephRx Corporation today announced issuance of a new U.S. patent for its novel peptide NX002, which currently is in preclinical development for the treatment of oral mucositis. Previously, NephRx reported that NX002 had demonstrated significantefficacy when tested in well-validated animal models of oral mucositis. Mucositis is a debilitating and often dose-limiting condition that affects more than 400,000 cancerpatients who receive chemotherapy or radiation therapy in the U.S. each year. Current treatment options are limited.
"Issuance of this most recent patent further confirms the promising utility of NX002 as a potential treatment for oral mucositis," said James Koziarz, President and CEO of NephRx. "Mucositis is a painful and debilitating side effect of cancer therapy that can be dose-limiting, jeopardizing patients' chances for successful treatment. We look forward to advancing the detailed NX002 toxicity studies needed to initiate the mucositis clinical program for NX002."
NX002 is a peptide derived from the naturally occurring growth factor AMP-18, which has been shown to stimulate the growth of epithelial cells and to promote mucosal wound healing after injury. Its multiple biological properties include the ability to protect cells from injury, stimulate cell growth and migration, and increase the accumulation of proteins that bind cells together. In a study in a well-validated mucositis model, animals treated with NX002 had reduced levels of oral ulceration and a more rapid recovery, with no evidence of toxicity. NephRx has begun the preclinicaltoxicology studies of NX002 needed to initiate mucositis clinical trials targeted for late 2011 or early 2012.
The U.S. Patent and Trademark office issued Patent No. 7910543, "Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors." Rights to this patent, which protects NX002 and related compounds, have been exclusively licensed to NephRx by the University of Chicago.
NX002 may also have applications in acute and chronic diseases of the gastrointestinal tract, such as Crohn's disease and ulcerative colitis. It has been shown to stimulate the growth of epithelial cells and to promote mucosal wound healing after injury.
SOURCE NephRx Corporation
NephRx黏膜发行公司今天宣布一项新的口服美国专利的新型肽NX002，其中目前正在治疗中的临床前开发阶段。此前，NephRx报道，NX002已经证明疗效显着，当黏膜炎动物模型试验验证的口头良好。黏膜炎是一种使人衰弱，经常剂量限制条件，影响到40多万癌症患者接受治疗谁在美国每年化疗或放疗。目前的治疗选择很有限。
“专利发行这进一步证实了最近的口腔粘膜炎的治疗有希望的效用NX002作为一个潜在的，” 詹姆斯说Koziarz，总裁兼首席执行官NephRx。 “粘膜炎是一种癌症治疗副作用的痛苦和衰弱，可剂量限制，危及成功治疗的病人的机会。我们期待着推进详细NX002 NX002毒性研究需要开展的粘膜炎的临床方案。”
NX002是从天然生长因子磷酸腺苷- 18，它已经显示出刺激上皮细胞的生长，并促进伤口愈合粘膜损伤后得出的肽。它的多种生物学特性包括：能够保护细胞不受损伤，刺激细胞的生长和迁移，并增加细胞蛋白质积累，结合在一起。在一个良好的口腔粘膜炎模型验证研究，NX002治疗的动物减少了口腔溃疡和更快速复苏的水平，没有毒性的证据。 NephRx已经开始为2011年底或2012年初启动所需要的口腔粘膜炎的临床试验临床前毒理学研究，有针对性的NX002。